Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28186559 | 0.78 | — | — | |
| SCHEMBL208499 | 0.69 | — | — | |
| SCHEMBL28177679 | 0.69 | — | — | |
| SCHEMBL1310229 | 0.67 | — | — | |
| Ammonia Solution, Strong SCHEMBL9456636 | 0.67 | — | — | |
| SCHEMBL2384882 | 0.67 | RAB9A (0.37) | RAB9ACHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL2778898 | 0.65 | RAB9A (0.46) | RAB9ACHRNB2CHRNA4CHRM2CHRM4 | |
| SCHEMBL919091 | 0.61 | — | — | |
| SCHEMBL5597606 | 0.61 | ALDH1A1 (0.38) | ALDH1A1TSHR | |
| SCHEMBL9229583 | 0.61 | RAB9A (0.37) | RAB9ACHRNB2CHRNA4CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8084486-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-12-27 | — | — | US | disclosed |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2011-08-11 | — | — | US | disclosed |
| US-7960426-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-06-14 | — | — | US | disclosed |
| US-7902232-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2011-03-08 | — | — | US | disclosed |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | PFIZER LIMITED (GB) | 2009-12-17 | — | — | US | disclosed |
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | ZOETIS SERVICES LLC | 2009-05-28 | — | — | US | disclosed |
| US-7514464-B2 | Substituted arylpyrazoles | PFIZER LIMITED (GB) | 2009-04-07 | — | — | US | disclosed |
| EP-1901608-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | Pfizer Limited (GB) | 2008-03-26 | — | — | EP | disclosed |
| WO-2006134466-A1 | SUBSTITUTED ARYLPYRAZOLES AS PARASITICIDAL AGENTS | PFIZER LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
| US-20060014802-A1 | Substituted arylpyrazoles | ZOETIS SERVICES LLC | 2006-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137524-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | RAB9A 44/4885CHRNB2 4176/4885CHRNA4 2931/4885 |
| US-20110196011-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP4X1, EPX, CYP2C9 | RAB9A 44/4885CHRNB2 4176/4885CHRNA4 2931/4885 |
| US-20060014802-A1 | Substituted arylpyrazoles | CYP4X1, ARG1, CYP2C9 | RAB9A 32/4885CHRNB2 4288/4885CHRNA4 3103/4885 |
| US-20090312371-A1 | SUBSTITUTED ARYLPYRAZOLES | CYP3A43, CYP3A4, CYP4X1 | RAB9A 1205/4885CHRNB2 4519/4885CHRNA4 3660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.